全文获取类型
收费全文 | 176717篇 |
免费 | 33434篇 |
国内免费 | 2463篇 |
专业分类
耳鼻咽喉 | 5567篇 |
儿科学 | 7432篇 |
妇产科学 | 3111篇 |
基础医学 | 6182篇 |
口腔科学 | 2005篇 |
临床医学 | 28081篇 |
内科学 | 52164篇 |
皮肤病学 | 8377篇 |
神经病学 | 15874篇 |
特种医学 | 7282篇 |
外科学 | 45141篇 |
综合类 | 1241篇 |
现状与发展 | 72篇 |
一般理论 | 12篇 |
预防医学 | 8427篇 |
眼科学 | 4697篇 |
药学 | 3254篇 |
中国医学 | 165篇 |
肿瘤学 | 13530篇 |
出版年
2024年 | 695篇 |
2023年 | 4930篇 |
2022年 | 1643篇 |
2021年 | 3887篇 |
2020年 | 6447篇 |
2019年 | 2681篇 |
2018年 | 8128篇 |
2017年 | 7800篇 |
2016年 | 9090篇 |
2015年 | 9016篇 |
2014年 | 16401篇 |
2013年 | 16726篇 |
2012年 | 7125篇 |
2011年 | 7233篇 |
2010年 | 11247篇 |
2009年 | 14924篇 |
2008年 | 7043篇 |
2007年 | 5352篇 |
2006年 | 7633篇 |
2005年 | 4869篇 |
2004年 | 4003篇 |
2003年 | 2913篇 |
2002年 | 2908篇 |
2001年 | 4517篇 |
2000年 | 3689篇 |
1999年 | 3811篇 |
1998年 | 3885篇 |
1997年 | 3636篇 |
1996年 | 3497篇 |
1995年 | 3347篇 |
1994年 | 2054篇 |
1993年 | 1699篇 |
1992年 | 1729篇 |
1991年 | 1800篇 |
1990年 | 1401篇 |
1989年 | 1543篇 |
1988年 | 1332篇 |
1987年 | 1135篇 |
1986年 | 1159篇 |
1985年 | 996篇 |
1984年 | 774篇 |
1983年 | 709篇 |
1982年 | 627篇 |
1981年 | 514篇 |
1980年 | 469篇 |
1979年 | 551篇 |
1978年 | 489篇 |
1977年 | 549篇 |
1975年 | 443篇 |
1972年 | 446篇 |
排序方式: 共有10000条查询结果,搜索用时 12 毫秒
81.
82.
Sameer Arora Kamal Shemisa Muthiah Vaduganathan Arman Qamar Ankur Gupta Sushil K. Garg Dharam J. Kumbhani Helen Mayo Houman Khalili Ambarish Pandey Sandeep R. Das 《Journal of the American College of Cardiology》2019,73(19):2454-2464
Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor. 相似文献
83.
84.
85.
Status migrainosus is defined by the international classification of headache disorders (ICHD) criteria as a debilitating migraine lasting more then 72 hours. The epidemiology of status migrainosus is still unknown in adult and children, and frequently underdiagnosed. Children and adolescents often end up in the emergency room with an intractable headache that failed outpatient therapy. Six to seven percent of these children do not respond to acute infusion therapy and require hospitalization. It is imperative that more aggressive therapy is considered when patients are affected by a severe intractable headache to prevent further disability and returning the child to baseline activity. Multiple therapies are available for adults and children. Studies for acute therapy in the emergency room are available in adults and pediatric groups. Small studies are available for inpatient therapy in children and, along with available therapies for children and adolescents, are described in this review. A review of the literature shows growing evidence regarding the use of dihydroergotamine intravenously once patients are hospitalized. Effectiveness and safety have been proven in the last decades in adults and small studies in the pediatric populations. 相似文献
86.
87.
Darren R. Feldman MD Yasser Ged MBBS Chung-Han Lee PhD Andrea Knezevic MS Ana M. Molina MD Ying-Bei Chen PhD Joshua Chaim DO Devyn T. Coskey MS Samuel Murray MS Satish K. Tickoo MD Victor E. Reuter MD Sujata Patil PhD Han Xiao MD Jahan Aghalar MD Arlyn J. Apollo MD Maria I. Carlo MD Robert J. Motzer MD Martin H. Voss MD 《Cancer》2020,126(24):5247-5255
88.
James I. Geller MD Joseph G. Pressey MD Malcolm A. Smith MD Rachel A. Kudgus PhD Mariana Cajaiba MD Joel M. Reid PhD David Hall PhD Donald A. Barkauskas PhD Stephen D. Voss MD Steve Y. Cho MD Stacey L. Berg MD Jeffrey S. Dome MD PhD Elizabeth Fox MD Brenda J. Weigel MD 《Cancer》2020,126(24):5303-5310
89.